Session 3: Drug-Gene and Drug-Drug-Gene Interactions (DGIs & DDGIs)
This session explores how genetic differences influence individual responses to medications, introducing key concepts of genetics, genomics, and pharmacogenomics. It examines how genetic variations and drug-gene interactions affect medication safety and effectiveness, highlighting the potential of genetic testing and gene editing for more personalised treatments. It also addresses ethical considerations and the importance of patient involvement in personalised medicine.
These materials have been developed within the EU-funded SafePolyMed project for educational, informational and non-commercial purposes only. They do not constitute medical advice and are not intended to replace consultation with a qualified healthcare professional. The SafePolyMed project received funding from the European Union’s Horizon Europe Research and Innovation Programme under Grant Agreement No. 101057639. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or the Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.
© SafePolyMed project partners, 2026. All rights reserved. Commercial reuse, redistribution or modification requires prior permission from the relevant rights holders.